Equity Overview
Price & Market Data
Price: $0.685
Daily Change: +$0.055 / 8.03%
Daily Range: $0.63 - $0.713
Market Cap: $11,996,177
Daily Volume: 936,236
Performance Metrics
1 Week: -8.33%
1 Month: -67.61%
3 Months: -79.10%
6 Months: -84.74%
1 Year: -92.80%
YTD: -91.94%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country:
Details
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.